Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy

Background: Angiotensin II (Ang II) has been shown in preclinical work to increase TGF-β production through AT1 receptor signaling and to decrease TGF-β through AT2 receptor signaling. Thus, the ang II pathway through overlap with the TGF-β pathway may have a critical role in carcinogenesis as well as immune evasion and inhibiting AT1 may enhance clinical responses in combination with PD(L)1 blockade. Here we report efficacy of anti PD(L)1 based...